Psychotropic Medication and Cognitive, Functional, and Neuropsychiatric Outcomes in Alzheimer's Disease (AD).

ABSTRACT:

Background/objectives

There are growing concerns about the safety and efficacy of psychotropic medications in Alzheimer's disease (AD). We sought to examine associations between psychotropic medication exposure and longitudinal change in cognitive, functional, and neuropsychiatric outcomes in a large clinical AD cohort.

Design

Longitudinal observational study.

Setting

National Alzheimer's Disease Coordinating Center combining data from 39 Alzheimer's disease centers.

Participants

8,034 participants with AD dementia.

Measurements

Mini-Mental State Exam (MMSE), Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB), and Neuropsychiatric Inventory Questionnaire (NPI-Q) Total. Probability of exposure to medication (the propensity score, PS) calculated via logi

SUBMITTER: Oh ES 

PROVIDER: S-EPMC8675538 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature